TY - JOUR T1 - Carboplatin and Weekly Paclitaxel in Non-small Cell Lung Cancer Patients Unfit for or Pretreated with Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 2555 LP - 2559 VL - 25 IS - 3C AU - GIANMAURO NUMICO AU - IDA COLANTONIO AU - MILENA GASCO AU - GIANFILIPPO BERTELLI AU - ORNELLA GARRONE AU - MARCELLA OCCELLI AU - ELENA FEA AU - GIANNA DI COSTANZO AU - CRISTINA GRANETTO AU - ABDELAMID HEOUAINE AU - ELVIO RUSSI AU - MARCO MERLANO Y1 - 2005/05/01 UR - http://ar.iiarjournals.org/content/25/3C/2555.abstract N2 - Background: Carboplatin-Paclitaxel is one of the most active regimens in non-small cell lung cancer (NSCLC). We assessed the administration of weekly Paclitaxel as second-line chemotherapy, or as first-line chemotherapy in unfit patients. Patients and Methods: Forty-eight patients received Carboplatin at the dose of 6 x area under the concentration-time curve (AUC) on day 1 and Paclitaxel 100 mg/m2 on days 1, 8, 15 every 28. Thirty-two had received a prior platinum-based treatment, while 16 were chemotherapy-naive, unfit patients. Results: Grade 3-4 neutropenia occurred in 16 patients (33%); grade 3-4 thrombocytopenia in 7 (15%); grade 1-3 peripheral sensory neuropathy in 35 (73%). Nineteen patients (39.6%; 95% C.I.: 25.8% - 53.4%) achieved an objective response without any difference between the first-line and second-line group. One-year survival was 39.5% (95% CI: 25.4% - 53.6%). Conclusion: The impressive activity of this regimen makes it suitable for further investigation in the second-line setting. Toxicity seen in the unfit population mandates some modification of the regimen. ER -